nach oben

Journal of Endocrinological Investigation

Erschienen in:

01.08.2015 | Review

Nonalcoholic fatty liver disease and decreased bone mineral density: is there a link?

verfasst von: G. Targher, A. Lonardo, M. Rossini

Erschienen in: Journal of Endocrinological Investigation | Ausgabe 8/2015

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Liver diseases are associated with decreased bone mineral density (BMD) and evidence suggests that nonalcoholic fatty liver disease (NAFLD) affects several extra-hepatic organs, interacting with the regulation of multiple endocrine and metabolic pathways. This review focuses on the rapidly expanding body of evidence that supports a strong association between NAFLD and the risk of decreased BMD, expression of low bone mass (osteoporosis), or reduced mineralization (osteomalacia).

Methods

We identified studies by searching PubMed for original articles published in English through March 2015 using the keywords “nonalcoholic fatty liver disease” or “fatty liver” combined with “bone mineral density”, “osteoporosis”, or “osteomalacia”.

Results

Recent cross-sectional and case–control studies involving both adults and children have consistently shown that patients with NAFLD exhibit a greater prevalence of decreased BMD compared with age-, sex-, and body mass index-matched healthy controls. Accumulating clinical and experimental evidence suggests that NAFLD may contribute to the pathophysiology of low BMD, possibly through the direct contribution of NAFLD to whole-body and hepatic insulin resistance and/or the systemic release of multiple pro-inflammatory, pro-coagulant, and pro-fibrogenic mediators.

Conclusions

Although more research is needed before firm conclusions can be drawn, it appears that there is a non-chance, statistical association between NAFLD and low BMD. This finding argues for more careful monitoring and evaluation of BMD among patients with NAFLD. The potential contribution of NAFLD itself to the development and progression of decreased BMD warrants further study.

Chalasani N, Younossi Z, Lavine JE, Diehl AM, Brunt EM, Cusi K, Charlton M, Sanyal AJ, American Association for the Study of Liver Diseases; American College of Gastroenterology; American Gastroenterological Association (2012) The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Am J Gastroenterol 107:811–826PubMedCrossRef

Anstee QM, Targher G, Day CP (2012) Progression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosis. Nat Rev Gastroenterol Hepatol 10:330–344CrossRef

Lonardo A, Ballestri S, Marchesini G, Angulo P, Loria P (2015) NAFLD a precursor of the metabolic syndrome. Dig Liv Dis 47:181–190CrossRef

Armstrong MJ, Adams LA, Canbay A, Syn WK (2014) Extrahepatic complications of nonalcoholic fatty liver disease. Hepatology 59:1174–1197PubMedCrossRef

Targher G, Day CP, Bonora E (2010) Risk of cardiovascular disease in patients with nonalcoholic fatty liver disease. N Engl J Med 363:1341–1350PubMedCrossRef

Targher G, Chonchol M, Pichiri I, Zoppini G (2011) Risk of cardiovascular disease and chronic kidney disease in diabetic patients with non-alcoholic fatty liver disease: just a coincidence? J Endocrinol Invest 34:544–551PubMed

Ballestri S, Lonardo A, Bonapace S, Byrne CD, Loria P, Targher G (2014) Risk of cardiovascular, cardiac and arrhythmic complications in patients with non-alcoholic fatty liver disease. World J Gastroenterol 20:1724–1745PubMedCentralPubMedCrossRef

Targher G, Chonchol MB, Byrne CD (2014) CKD and nonalcoholic fatty liver disease. Am J Kidney Dis 64:638–652PubMedCrossRef

Pirgon O, Bilgin H, Tolu I, Odabas D (2011) Correlation of insulin sensitivity with bone mineral status in obese adolescents with nonalcoholic fatty liver disease. Clin Endocrinol (Oxf) 75:189–195CrossRef

10.

Campos RM, de Piano A, da Silva PL, Carnier J, Sanches PL, Corgosinho FC, Masquio DC, Lazaretti-Castro M, Oyama LM, Nascimento CM, Tock L, de Mello MT, Tufik S, Dâmaso AR (2012) The role of pro/anti-inflammatory adipokines on bone metabolism in NAFLD obese adolescents: effects of long-term interdisciplinary therapy. Endocrine 42:146–156PubMedCrossRef

11.

Pardee PE, Dunn W, Schwimmer JB (2012) Non-alcoholic fatty liver disease is associated with low bone mineral density in obese children. Aliment Pharmacol Ther 35:248–254PubMedCrossRef

12.

Purnak T, Beyazit Y, Ozaslan E, Efe C, Hayretci M (2012) The evaluation of bone mineral density in patients with nonalcoholic fatty liver disease. Wien Klin Wochenschr 124:526–531PubMedCrossRef

13.

Moon SS, Lee YS, Kim SW (2012) Association of nonalcoholic fatty liver disease with low bone mass in postmenopausal women. Endocrine 42:423–429PubMedCrossRef

14.

Li M, Xu Y, Xu M, Ma L, Wang T, Liu Y, Dai M, Chen Y, Lu J, Liu J, Bi Y, Ning G (2012) Association between nonalcoholic fatty liver disease (NAFLD) and osteoporotic fracture in middle-aged and elderly Chinese. J Clin Endocrinol Metab 97:2033–2038PubMedCrossRef

15.

Pacifico L, Bezzi M, Lombardo CV, Romaggioli S, Ferraro F, Bascetta S, Chiesa C (2013) Adipokines and C-reactive protein in relation to bone mineralization in pediatric nonalcoholic fatty liver disease. World J Gastroenterol 19:4007–4014PubMedCentralPubMedCrossRef

16.

Bhatt SP, Nigam P, Misra A, Guleria R, Qadar Pasha MA (2013) Independent associations of low 25-hydroxyvitamin D and high parathyroid hormonal levels with nonalcoholic fatty liver disease in Asian Indians residing in north India. Atherosclerosis 230:157–163PubMedCrossRef

17.

Cui R, Sheng H, Rui XF, Cheng XY, Sheng CJ, Wang JY, Qu S (2013) Low bone mineral density in Chinese adults with nonalcoholic fatty liver disease. Int J Endocrinol 2013:396545PubMedCentralPubMedCrossRef

18.

de Paula FJ, Horowitz MC, Rosen CJ (2010) Novel insights into the relationship between diabetes and osteoporosis. Diabetes Metab Res Rev 26:622–630PubMedCentralPubMedCrossRef

19.

Arikan S, Tuzcu A, Bahceci M, Ozmen S, Gokalp D (2012) Insulin resistance in type 2 diabetes mellitus may be related to bone mineral density. J Clin Densitom 15:186–190PubMedCrossRef

20.

Faulhaber GA, Premaor MO, Moser Filho HL, Silla LM, Furlanetto TW (2009) Low bone mineral density is associated with insulin resistance in bone marrow transplant subjects. Bone Marrow Transpl 43:953–957CrossRef

21.

Greco EA, Francomano D, Fornari R, Marocco C, Lubrano C, Papa V, Wannenes F, Di Luigi L, Donini LM, Lenzi A, Aversa A, Migliaccio S (2013) Negative association between trunk fat, insulin resistance and skeleton in obese women. World J Diabetes 4:31–39PubMedCentralPubMedCrossRef

22.

Redlich K, Smolen JS (2012) Inflammatory bone loss: pathogenesis and therapeutic intervention. Nat Rev Drug Discov 11:234–250PubMedCrossRef

23.

Zou W, Hakim I, Tschoep K, Endres S, Bar-Shavit Z (2001) Tumor necrosis factor-alpha mediates RANK ligand stimulation of osteoclast differentiation by an autocrine mechanism. J Cell Biochem 83:70–83PubMedCrossRef

24.

Nanes MS (2003) Tumor necrosis factor-alpha: molecular and cellular mechanisms in skeletal pathology. Gene 321:1–15PubMedCrossRef

25.

Lee HL, Yi T, Woo KM, Ryoo HM, Kim GS, Baek JH (2010) Msx2 mediates the inhibitory action of TNF alpha on osteoblast differentiation. Exp Mol Med 42:437–445PubMedCentralPubMedCrossRef

26.

Ochi H, Hara Y, Tagawa M, Shinomiya K, Asou Y (2010) The roles of TNFR1 in lipopolysaccharide induced bone loss: dual effects of TNFR1 on bone metabolism via osteoclastogenesis and osteoblast survival. J Orthop Res 28:657–663PubMed

27.

Peterson CA, Heffernan ME (2008) Serum tumor necrosis factor-alpha concentrations are negatively correlated with serum 25(OH)D concentrations in healthy women. J Inflamm (Lond) 5:10CrossRef

28.

Syn WK, Choi SS, Liaskou E, Karaca GF, Agboola KM, Oo YH, Mi Z, Pereira TA, Zdanowicz M, Malladi P, Chen Y, Moylan C, Jung Y, Bhattacharya SD, Teaberry V, Omenetti A, Abdelmalek MF, Guy CD, Adams DH, Kuo PC, Michelotti GA, Whitington PF, Diehl AM (2011) Osteopontin is induced by hedgehog pathway activation and promotes fibrosis progression in nonalcoholic steatohepatitis. Hepatology 53:106–115PubMedCentralPubMedCrossRef

29.

Fujisawa R, Tamura M (2012) Acidic bone matrix proteins and their roles in calcification. Front Biosci 17:1891–1903CrossRef

30.

Ishijima M, Rittling SR, Yamashita T, Tsuji K, Kurosawa H, Nifuji A, Denhardt DT, Noda M (2001) Enhancement of osteoclastic bone resorption and suppression of osteoblastic bone formation in response to reduced mechanical stress do not occur in the absence of osteopontin. J Exp Med 193:399–404PubMedCentralPubMedCrossRef

31.

Confavreux CB (2011) Bone: from a reservoir of minerals to a regulator of energy metabolism. Kidney Int 79(suppl 121):S14–S19CrossRef

32.

Chapman J, Miles PD, Ofrecio JM, Neels JG, Yu JG, Resnik JL, Wilkes J, Talukdar S, Thapar D, Johnson K, Sears DD (2010) Osteopontin is required for the early onset of high fat diet-induced insulin resistance in mice. PLoS One 5:e13959PubMedCentralPubMedCrossRef

33.

Chang IC, Chiang TI, Yeh KT, Lee H, Cheng YW (2010) Increased serum osteopontin is a risk factor for osteoporosis in menopausal women. Osteoporos Int 21:1401–1409PubMedCrossRef

34.

Kennedy OD, Brennan O, Rackard SM, Staines A, O’Brien FJ, Taylor D, Lee TC (2009) Effects of ovariectomy on bone turnover, porosity, and biomechanical properties in ovine compact bone 12 months postsurgery. J Orthop Res 27:303–309PubMedCrossRef

35.

Reid P, Holen I (2009) Pathophysiological roles of osteoprotegerin (OPG). Eur J Cell Biol 88:1–17PubMedCrossRef

36.

Blázquez-Medela AM, López-Novoa JM, Martínez-Salgado C (2011) Osteoprotegerin and diabetes associated pathologies. Curr Mol Med 11:401–416PubMedCrossRef

37.

Yilmaz Y, Yonal O, Kurt R, Oral AY, Eren F, Ozdogan O, Ari F, Celikel CA, Korkmaz S, Ulukaya E, Imeryuz N, Kalayci C, Avsar E (2010) Serum levels of osteoprotegerin in the spectrum of nonalcoholic fatty liver disease. Scand J Clin Lab Invest 70:541–546PubMedCrossRef

38.

Patterson-Buckendahl P (2011) Osteocalcin is a stress-responsive neuropeptide. Endocr Regul 45:99–110PubMedCrossRef

39.

Pietschmann P, Resch H, Krexner E, Woloszczuk W, Willvonseder R (1991) Decreased serum osteocalcin levels in patients with postmenopausal osteoporosis. Acta Med Austriaca 18:114–116PubMed

40.

Fernandez-Real JM, Ortega F, Gómez-Ambrosi J, Salvador J, Frühbeck G, Ricart W (2010) Circulating osteocalcin concentrations are associated with parameters of liver fat infiltration and increase in parallel to decreased liver enzymes after weight loss. Osteoporos Int 21:2101–2107PubMedCrossRef

41.

Yilmaz Y, Kurt R, Eren F, Imeryuz N (2011) Serum osteocalcin levels in patients with nonalcoholic fatty liver disease: association with ballooning degeneration. Scand J Clin Lab Invest 71:631–636PubMedCrossRef

42.

Dou J, Ma X, Fang Q, Hao Y, Yang R, Wang F, Zhu J, Bao Y, Jia W (2013) Relationship between serum osteocalcin levels and non-alcoholic fatty liver disease in Chinese men. Clin Exp Pharmacol Physiol 40:282–288PubMedCrossRef

43.

Minokoshi Y, Kim YB, Peroni OD, Fryer LG, Müller C, Carling D, Kahn BB (2002) Leptin stimulates fatty-acid oxidation by activating AMP-activated protein kinase. Nature 415:339–343PubMedCrossRef

44.

Ebihara K, Kusakabe T, Hirata M, Masuzaki H, Miyanaga F, Kobayashi N, Tanaka T, Chusho H, Miyazawa T, Hayashi T, Hosoda K, Ogawa Y, DePaoli AM, Fukushima M, Nakao K (2007) Efficacy and safety of leptin-replacement therapy and possible mechanisms of leptin actions in patients with generalized lipodystrophy. J Clin Endocrinol Metab 92:532–541PubMedCrossRef

45.

Polyzos SA, Kountouras J, Mantzoros CS (2015) Leptin in nonalcoholic fatty liver disease: a narrative review. Metabolism 64:60–78PubMedCrossRef

46.

Yadav VK, Oury F, Suda N, Liu ZW, Gao XB, Confavreux C, Klemenhagen KC, Tanaka KF, Gingrich JA, Guo XE, Tecott LH, Mann JJ, Hen R, Horvath TL, Karsenty G (2009) A serotonin-dependent mechanism explains the leptin regulation of bone mass, appetite, and energy expenditure. Cell 138:976–989PubMedCentralPubMedCrossRef

47.

Zeadin MG, Butcher MK, Shaughnessy SG, Werstuck GH (2012) Leptin promotes osteoblast differentiation and mineralization of primary cultures of vascular smooth muscle cells by inhibiting glycogen synthase kinase (GSK)-3b. Biochem Biophys Res Commun 425:924–930PubMedCrossRef

48.

DeMambro VE, Maile L, Wai C, Kawai M, Cascella T, Rosen CJ, Clemmons D (2012) Insulin-like growth factor-binding protein-2 is required for osteoclast differentiation. J Bone Miner Res 27:390–400PubMedCentralPubMedCrossRef

49.

Tsuji K, Maeda T, Kawane T, Matsunuma A, Horiuchi N (2010) Leptin stimulates fibroblast growth factor-23 expression in bone and suppresses renal 1alpha,25-dihydroxyvitamin D3 synthesis in leptin-deficient ob/ob mice. J Bone Miner Res 25:1711–1723PubMedCrossRef

50.

Dimitri P, Jacques RM, Paggiosi M, King D, Walsh J, Taylor ZA, Frangi AF, Bishop N, Eastell R (2014) Leptin may play a role in bone microstructural alterations in obese children. J Clin Endocrinol Metab 100:594–602PubMedCrossRef

51.

Musso G, Gambino R, Cassader M (2010) Emerging molecular targets for the treatment of non-alcoholic fatty liver disease. Annu Rev Med 61:375–392PubMedCrossRef

52.

Ramezani-Moghadam M, Wang J, Ho V, Iseli TJ, Alzahrani B, Xu A, van der Poorten D, Qiao L, George J, Hebbard L (2015) Adiponectin reduces hepatic stellate cell migration by promoting tissue inhibitor of metalloproteinase-1 (TIMP-1) secretion. J Biol Chem 290:5533–5542PubMedCrossRef

53.

Luo XH, Guo LJ, Xie H, Yuan LQ, Wu XP, Zhou HD, Liao EY (2006) Adiponectin stimulates RANKL and inhibits OPG expression in human osteoblasts through the MAPK signaling pathway. J Bone Miner Res 21:1648–1656PubMedCrossRef

54.

Williams GA, Wang Y, Callon KE, Watson M, Lin JM, Lam JB, Costa JL, Orpe A, Broom N, Naot D, Reid IR, Cornish J (2009) In vitro and in vivo effects of adiponectin on bone. Endocrinology 150:3603–3610PubMedCrossRef

55.

Wang QP, Yang L, Li XP, Xie H, Liao EY, Wang M, Luo XH (2012) Effects of 17-beta-estradiol on adiponectin regulation of the expression of osteoprotegerin and receptor activator of nuclear factor-kB ligand. Bone 51:515–523PubMedCrossRef

56.

Tu Q, Zhang J, Dong LQ, Saunders E, Luo E, Tang J, Chen J (2011) Adiponectin inhibits osteoclastogenesis and bone resorption via APPL1-mediated suppression of Akt1. J Biol Chem 286:12542–12553PubMedCentralPubMedCrossRef

57.

Targher G, Pichiri I, Lippi G (2012) Vitamin D, thrombosis, and hemostasis: more than skin deep. Semin Thromb Hemost 38:114–124PubMedCrossRef

58.

Targher G, Bertolini L, Scala L, Cigolini M, Zenari L, Falezza G, Arcaro G (2007) Associations between serum 25-hydroxyvitamin D3 concentrations and liver histology in patients with nonalcoholic fatty liver disease. Nutr Metab Cardiovasc Dis 17:517–524PubMedCrossRef

59.

Barchetta I, Angelico F, Del Ben M, Baroni MG, Pozzilli P, Morini S (2011) Cavallo MG (2011) Strong association between non-alcoholic fatty liver disease (NAFLD) and low 25(OH)-vitamin D levels in an adult population with normal serum liver enzymes. BMC Med 9:85PubMedCentralPubMedCrossRef

60.

Targher G, Scorletti E, Mantovani A, Byrne CD (2013) Nonalcoholic fatty liver disease and reduced serum vitamin D3 levels. Metab Syndr Relat Disord 11:217–228PubMedCrossRef

61.

Nobili V, Giorgio V, Liccardo D, Bedogni G, Morino G, Alisi A, Cianfarani S (2014) Vitamin D levels and liver histological alterations in children with nonalcoholic fatty liver disease. Eur J Endocrinol 170:547–553PubMedCrossRef

62.

Barchetta I, Carotti S, Labbadia G, Gentilucci UV, Muda AO, Angelico F, Silecchia G, Leonetti F, Fraioli A, Picardi A, Morini S, Cavallo MG (2012) Liver vitamin D receptor, CYP2R1, and CYP27A1 expression: relationship with liver histology and vitamin D3 levels in patients with nonalcoholic steatohepatitis or hepatitis C virus. Hepatology 56:2180–2187PubMedCrossRef

63.

Laird E, McNulty H, Ward M, Hoey L, Mc Sorley E, Wallace JM, Carson E, Molloy AM, Healy M, Casey MC, Cunningham C, Strain JJ (2014) Vitamin D deficiency is associated with inflammation in older Irish adults. J Clin Endocrinol Metab 99:1807–1815PubMedCrossRef

64.

Villaggio B, Soldano S, Cutolo M (2012) 1,25-dihydroxyvitamin D3 down-regulates aromatase expression and inflammatory cytokines in human macrophages. Clin Exp Rheumatol 30:934–938PubMed

65.

Hallsworth K, Thoma C, Moore S, Ploetz T, Anstee QM, Taylor R, Day CP, Trenell MI (2015) Nonalcoholic fatty liver disease is associated with higher levels of objectively measured sedentary behaviour and lower levels of physical activity than matched healthy controls. Frontline Gastroenterol 6:44–51PubMedCentralPubMedCrossRef

66.

Chastin SF, Mandrichenko O, Helbostadt JL, Skelton DA (2014) Associations between objectively measured sedentary behaviour and physical activity with bone mineral density in adults and older adults, the NHANES study. Bone 64:254–262PubMedCrossRef

67.

Choudhary NS, Tomar M, Chawla YK, Bhadada SK, Khandelwal N, Dhiman RK, Duseja A, Bhansali A (2011) Hepatic osteodystrophy is common in patients with noncholestatic liver disease. Dig Dis Sci 56:3323–3327PubMedCrossRef

68.

Santori C, Ceccanti M, Diacinti D, Attilia ML, Toppo L, D’Erasmo E, Romagnoli E, Mascia ML, Cipriani C, Prastaro A, Carnevale V, Minisola S (2008) Skeletal turnover, bone mineral density, and fractures in male chronic abusers of alcohol. J Endocrinol Invest 31:321–326PubMedCrossRef

69.

Yurci A, Yucesoy M, Unluhizarci K, Torun E, Gursoy S, Baskol M, Guven K, Ozbakir O (2011) Effects of testosterone gel treatment in hypogonadal men with liver cirrhosis. Clin Res Hepatol Gastroenterol 35:845–854PubMedCrossRef

70.

Bang UC, Benfield T, Bendtsen F, Hyldstrup L, Beck Jensen JE (2014) The risk of fractures among patients with cirrhosis or chronic pancreatitis. Clin Gastroenterol Hepatol 12:320–326PubMedCrossRef

71.

Sinclair M, Grossmann M, Gow PJ, Angus PW (2015) Testosterone in men with advanced liver disease: abnormalities and implications. J Gastroenterol Hepatol 30:244–251PubMedCrossRef

72.

Lonardo A, Adinolfi LE, Loria P, Carulli N, Ruggiero G, Day CP (2004) Steatosis and hepatitis C virus: mechanisms and significance for hepatic and extra-hepatic disease. Gastroenterology 126:586–597PubMedCrossRef

73.

Lonardo A, Adinolfi LE, Restivo L, Ballestri S, Romagnoli D, Baldelli E, Nascimbeni F, Loria P (2014) Pathogenesis and significance of hepatitis C virus steatosis: an update on survival strategy of a successful pathogen. World J Gastroenterol 20:7089–7103PubMedCentralPubMedCrossRef

74.

Orsini LG, Pinheiro MM, Castro CH, Silva AE, Szejnfeld VL (2013) Bone mineral density measurements, bone markers and serum vitamin D concentrations in men with chronic non-cirrhotic untreated hepatitis C. PLoS One 8:e81652PubMedCentralPubMedCrossRef

75.

Ohlsson C, Sjögren K (2015) Effects of the gut microbiota on bone mass. Trends Endocrinol Metab 26:69–74PubMedCrossRef

76.

Mehal WZ (2013) The Gordian Knot of dysbiosis, obesity and NAFLD. Nat Rev Gastroenterol Hepatol 10:637–644PubMedCrossRef

77.

Matsubara T, Li F, Gonzalez FJ (2013) FXR signaling in the enterohepatic system. Mol Cell Endocrinol 368:17–29PubMedCentralPubMedCrossRef

78.

Li T, Chiang JY (2015) Bile acids as metabolic regulators. Curr Opin Gastroenterol 31:159–165PubMedCrossRef

Titel: Nonalcoholic fatty liver disease and decreased bone mineral density: is there a link?
verfasst von: G. Targher
A. Lonardo
M. Rossini
Publikationsdatum: 01.08.2015
Verlag: Springer International Publishing
Erschienen in: Journal of Endocrinological Investigation / Ausgabe 8/2015
Elektronische ISSN: 1720-8386
DOI: https://doi.org/10.1007/s40618-015-0315-6

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Echinokokkose medikamentös behandeln oder operieren?

06.05.2024 DCK 2024 Kongressbericht

Die Therapie von Echinokokkosen sollte immer in spezialisierten Zentren erfolgen. Eine symptomlose Echinokokkose kann – egal ob von Hunde- oder Fuchsbandwurm ausgelöst – konservativ erfolgen. Wenn eine Op. nötig ist, kann es sinnvoll sein, vorher Zysten zu leeren und zu desinfizieren.

Umsetzung der POMGAT-Leitlinie läuft

03.05.2024 DCK 2024 Kongressbericht

Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.

Proximale Humerusfraktur: Auch 100-Jährige operieren?

01.05.2024 DCK 2024 Kongressbericht

Mit dem demographischen Wandel versorgt auch die Chirurgie immer mehr betagte Menschen. Von Entwicklungen wie Fast-Track können auch ältere Menschen profitieren und bei proximaler Humerusfraktur können selbst manche 100-Jährige noch sicher operiert werden.

Die „Zehn Gebote“ des Endokarditis-Managements

30.04.2024 Endokarditis Leitlinie kompakt

Worauf kommt es beim Management von Personen mit infektiöser Endokarditis an? Eine Kardiologin und ein Kardiologe fassen die zehn wichtigsten Punkte der neuen ESC-Leitlinie zusammen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Purpose

Methods

Results

Conclusions

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 8/2015

Analysis of RAS mutation and PAX8/PPARγ rearrangements in follicular-derived thyroid neoplasms in a Korean population: frequency and ultrasound findings

Effects of monobutyl phthalate on steroidogenesis through steroidogenic acute regulatory protein regulated by transcription factors in mouse Leydig tumor cells

Psychosine inhibits osteoclastogenesis and bone resorption via G protein-coupled receptor 65

Association between nonalcoholic fatty liver disease and bone mineral density: a systematic review and meta-analysis

Analysis of renal functions and proteinuria in young obese adults